Trial Profile
Pegasys [peginterferon alfa-2a] plus entecavir versus entecavir alone for hepatitis Be antigen-positive chronic hepatitis B
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- 28 Apr 2013 Interim results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 29 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Feb 2008 New trial record.